Abion Inc.

A203400

KR7203400007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
8,270 ^KRW	+0.85%		+8.96%	-1.90%

2023	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI
2023	TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc.	CI

Abion Inc. announced that it has received KRW 7 billion in funding from Hanwha Investment & Securities Co., Ltd., MAGNA Investment Co., Ltd., Axis Investment Co., Ltd.

August 06, 2020

On August 7, 2020, Abion Inc. (XKON:A203400) closed the transaction.

Latest news about Abion Inc.

Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	12-27	CI
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc.	12-26	CI
Gencurix Inc. announced that it has received KRW 2 billion in funding from Abion Inc.	12-26	CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 6 billion in funding from Abion Inc.	12-25	CI
Gencurix Inc. announced that it expects to receive KRW 2 billion in funding from Abion Inc.	12-25	CI
Abion Inc. announced that it has received KRW 8.499991272 billion in funding	12-25	CI
Abion Inc. announced that it expects to receive KRW 8.499991272 billion in funding	12-17	CI
ABION Presents New Efficacy Data for ABN401	13/10/23	CI
Abion Inc. announced that it expects to receive KRW 21 billion in funding from LabGenomics Co., Ltd., Atinum Investment Co., Ltd, NH Investment & Securities Co., Ltd., Investment and others	10/04/23	CI
Abion Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
Abion Inc. Auditor Raises 'Going Concern' Doubt	20/03/23	CI
Abion Inc. announced that it has received KRW 5.8 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm	05/11/20	CI
Abion Inc. announced that it expects to receive KRW 5.8 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm and other investors	28/10/20	CI
Abion Inc. announced that it has received KRW 7 billion in funding from Hanwha Investment & Securities Co., Ltd., MAGNA Investment Co., Ltd., Axis Investment Co., Ltd.	06/08/20	CI
Abion Inc. announced that it expects to receive KRW 7 billion in funding from Hanwha Investment & Securities Co., Ltd., MAGNA Investment Co., Ltd., Axis Investment Co., Ltd.	02/08/20	CI
TELCON RF PHARMACEUTICAL. Inc. acquired an additional 3.73% stake in Abion Inc. from Leeds Investments Inc. and an individual for KRW 2.8 billion.	02/07/20	CI
St-Stassets Health Care Fund No.1 cancelled the acquisition of an unknown stake in Abion Inc. from KPM TECH Co., Ltd.	08/05/20	CI
St-Stassets Health Care Fund No.1 and 27 other buyers acquired 32.04% stake in Abion Inc. from KPM TECH Co., Ltd. for KRW 24.4 billion.	30/05/19	CI
Abion Inc. announced that it has received KRW 8.999953 billion in funding	29/05/19	CI
Abion Inc. announced that it expects to receive KRW 8.999953 billion in funding	08/05/19	CI
St-Stassets Health Care Fund No.1 signed a contract to acquire an unknown stake in Abion Inc. from KPM TECH Co., Ltd. for KRW 14.5 billion.	08/05/19	CI
KPM TECH Co., Ltd. acquired 25.9% stake in Abion Inc. from a group of sellers for KRW 13.5 billion.	30/08/17	CI
Abion Inc. cancelled the acquisition of NH Special Purpose Acquisition 8 Co., Ltd. in a reverse merger transaction.	19/01/17	CI
Abion Inc. agreed to acquire NH Special Purpose Acquisition 8 Co., Ltd. in a reverse merger transaction.	05/10/16	CI
KoFC-IMM R&D-Biz Creation 2013-2 Venture Capital Fund managed by IMM Investment Corp. sold 3.7% stake in Abion Inc. for KRW 2.8 billion.	03/08/15	CI

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Sector

Biotechnology & Medical Research

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABION INC.	-1.90%	132M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B